158 related articles for article (PubMed ID: 34885165)
1. Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" Trial.
Lee CJ; Modave E; Boeckx B; Stacchiotti S; Rutkowski P; Blay JY; Debiec-Rychter M; Sciot R; Lambrechts D; Wozniak A; Schöffski P
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885165
[TBL] [Abstract][Full Text] [Related]
2. Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 "CREATE" Trial.
Lee CJ; Modave E; Boeckx B; Kasper B; Aamdal S; Leahy MG; Rutkowski P; Bauer S; Debiec-Rychter M; Sciot R; Lambrechts D; Wozniak A; Schöffski P
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628499
[TBL] [Abstract][Full Text] [Related]
3. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.
Schöffski P; Wozniak A; Stacchiotti S; Rutkowski P; Blay JY; Lindner LH; Strauss SJ; Anthoney A; Duffaud F; Richter S; Grünwald V; Leahy MG; Reichardt P; Sufliarsky J; van der Graaf WT; Sciot R; Debiec-Rychter M; van Cann T; Marréaud S; Lia M; Raveloarivahy T; Collette L; Bauer S
Ann Oncol; 2017 Dec; 28(12):3000-3008. PubMed ID: 28950372
[TBL] [Abstract][Full Text] [Related]
4. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.
Schöffski P; Wozniak A; Kasper B; Aamdal S; Leahy MG; Rutkowski P; Bauer S; Gelderblom H; Italiano A; Lindner LH; Hennig I; Strauss S; Zakotnik B; Anthoney A; Albiges L; Blay JY; Reichardt P; Sufliarsky J; van der Graaf WTA; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Raveloarivahy T; Collette S; Stacchiotti S
Ann Oncol; 2018 Mar; 29(3):758-765. PubMed ID: 29216400
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
[TBL] [Abstract][Full Text] [Related]
6. Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study.
Shimokawa M; Nosaki K; Seto T; Ohashi K; Morise M; Horinouchi H; Sakakibara J; Murakami H; Yano S; Satouchi M; Matsumoto S; Goto K; Yoh K
Trials; 2020 Mar; 21(1):298. PubMed ID: 32228679
[TBL] [Abstract][Full Text] [Related]
7. The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response.
Devecchi A; De Cecco L; Dugo M; Penso D; Dagrada G; Brich S; Stacchiotti S; Sensi M; Canevari S; Pilotti S
Cancer Commun (Lond); 2018 Nov; 38(1):70. PubMed ID: 30486883
[TBL] [Abstract][Full Text] [Related]
8. The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.
Schöffski P; Wozniak A; Leahy MG; Aamdal S; Rutkowski P; Bauer S; Richter S; Grünwald V; Debiec-Rychter M; Sciot R; Geoerger B; Marréaud S; Collette S; Nzokirantevye A; Strauss SJ
Eur J Cancer; 2018 May; 94():156-167. PubMed ID: 29567632
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib in Patients With MET-Amplified NSCLC.
Camidge DR; Otterson GA; Clark JW; Ignatius Ou SH; Weiss J; Ades S; Shapiro GI; Socinski MA; Murphy DA; Conte U; Tang Y; Wang SC; Wilner KD; Villaruz LC
J Thorac Oncol; 2021 Jun; 16(6):1017-1029. PubMed ID: 33676017
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
Kang J; Chen HJ; Zhang XC; Su J; Zhou Q; Tu HY; Wang Z; Wang BC; Zhong WZ; Yang XN; Chen ZH; Ding Y; Wu X; Wang M; Fu JG; Yang Z; Zhang X; Shao YW; Wu YL; Yang JJ
Thorac Cancer; 2018 Sep; 9(9):1093-1103. PubMed ID: 29978950
[TBL] [Abstract][Full Text] [Related]
11. Genomic and clinical characteristics of
Cheng T; Gu Z; Song D; Liu S; Tong X; Wu X; Lin Z; Hong W
J Cancer; 2021; 12(3):644-651. PubMed ID: 33403024
[No Abstract] [Full Text] [Related]
12. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib in
Landi L; Chiari R; Tiseo M; D'Incà F; Dazzi C; Chella A; Delmonte A; Bonanno L; Giannarelli D; Cortinovis DL; de Marinis F; Borra G; Morabito A; Gridelli C; Galetta D; Barbieri F; Grossi F; Capelletto E; Minuti G; Mazzoni F; Verusio C; Bria E; Alì G; Bruno R; Proietti A; Fontanini G; Crinò L; Cappuzzo F
Clin Cancer Res; 2019 Dec; 25(24):7312-7319. PubMed ID: 31416808
[TBL] [Abstract][Full Text] [Related]
14. Crizotinib-resistant
Shen B; Wu F; Ye J; Liang R; Wang R; Yu R; Wu X; Shao YW; Feng J
Future Oncol; 2019 Aug; 15(22):2585-2593. PubMed ID: 31339066
[No Abstract] [Full Text] [Related]
15. MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel
Chu LP; Franck D; Parachoniak CA; Gregg JP; Moore MG; Farwell DG; Rao S; Heilmann AM; Erlich RL; Ross JS; Miller VA; Ali S; Riess JW
Oncologist; 2019 Oct; 24(10):1305-1308. PubMed ID: 31391294
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.
Du J; Wu X; Tong X; Wang X; Wei J; Yang Y; Chang Z; Mao Y; Shao YW; Liu B
Oncotarget; 2017 Apr; 8(16):26281-26287. PubMed ID: 28460431
[TBL] [Abstract][Full Text] [Related]
17. Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer.
Parsons BM; Meier DR; Richmond CS; Gurda GT; Lofgren KA; Burkard ME; Deming DA; Kenny PA
Clin Breast Cancer; 2020 Aug; 20(4):e433-e438. PubMed ID: 32234363
[TBL] [Abstract][Full Text] [Related]
18. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Liu X; Jia Y; Stoopler MB; Shen Y; Cheng H; Chen J; Mansukhani M; Koul S; Halmos B; Borczuk AC
J Clin Oncol; 2016 Mar; 34(8):794-802. PubMed ID: 26215952
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
[TBL] [Abstract][Full Text] [Related]
20. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
